Latest News and Press Releases

NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq:...

NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today...

NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today...

New subsidiary Veris acquires privately held oncology digital health company Oncodisc Inc. Technologies include first intelligent implantable vascular access port with biologic sensors and...

NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, and its major subsidiary...

NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today...

Initial NYU experience in 99 patients demonstrated EsoCheck and EsoGuard capable of detecting esophageal precancer in chronic heartburn patients NEW YORK, May 24, 2021 (GLOBE NEWSWIRE) --...

Conference call to be held today at 4:30 PM EDT NEW YORK, May 17, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product,...

Dr. David Poppers to present on his initial experience with Lucid’s EsoCheck and EsoGuard NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed” or the “Company”),...

Four new senior executives will support growth strategy focused on multi-channel EsoGuard commercialization NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ)...